ARL5B

Summary

ARL5B (ARF like GTPase 5B, HGNC:23052) is a protein-coding gene on chromosome 10p12.31, encoding ADP-ribosylation factor-like protein 5B (Q96KC2). Binds and exchanges GTP and GDP.

ARL5B (ARL8) belongs to a family of proteins that are structurally similar to ADP-ribosylation factors (ARFs; see MIM 103180). ARLs and ARFs are part of the RAS superfamily of regulatory GTPases.

Source: NCBI Gene 221079 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 27 total
• MANE Select transcript: NM_178815

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23052
Approved symbol	ARL5B
Name	ARF like GTPase 5B
Location	10p12.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000165997
Ensembl biotype	protein_coding
OMIM	608909
Entrez	221079

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000377275, ENST00000867148

RefSeq mRNA: 1 — MANE Select: NM_178815 NM_178815

CCDS: CCDS7131

Canonical transcript exons

ENST00000377275 — 6 exons

Exon	Start	End
ENSE00001098821	18668530	18668677
ENSE00001098822	18672622	18672705
ENSE00001098823	18673984	18674135
ENSE00001120931	18659431	18659683
ENSE00001473373	18675168	18681639
ENSE00001713306	18666575	18666635

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 96.62.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.7405 / max 873.8714, expressed in 1803 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104143	24.4604	1796
104142	1.8337	1014
104144	1.8225	684
104145	0.5424	284
104146	0.0815	24

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vena cava	UBERON:0004087	96.62	gold quality
epithelial cell of pancreas	CL:0000083	96.53	gold quality
cartilage tissue	UBERON:0002418	96.49	gold quality
pancreatic ductal cell	CL:0002079	95.35	gold quality
ileal mucosa	UBERON:0000331	93.77	gold quality
adrenal tissue	UBERON:0018303	93.71	gold quality
tibialis anterior	UBERON:0001385	93.57	gold quality
pericardium	UBERON:0002407	92.95	gold quality
secondary oocyte	CL:0000655	92.62	gold quality
amniotic fluid	UBERON:0000173	92.43	gold quality
epithelium of nasopharynx	UBERON:0001951	91.42	gold quality
endothelial cell	CL:0000115	91.39	gold quality
parietal pleura	UBERON:0002400	91.24	gold quality
tibia	UBERON:0000979	91.18	gold quality
upper leg skin	UBERON:0004262	91.12	gold quality
esophagus squamous epithelium	UBERON:0006920	90.97	gold quality
jejunal mucosa	UBERON:0000399	90.93	gold quality
visceral pleura	UBERON:0002401	90.45	gold quality
oviduct epithelium	UBERON:0004804	89.98	gold quality
gingiva	UBERON:0001828	89.26	gold quality
palpebral conjunctiva	UBERON:0001812	89.11	gold quality
gingival epithelium	UBERON:0001949	89.05	gold quality
thymus	UBERON:0002370	89.01	gold quality
deltoid	UBERON:0001476	88.62	gold quality
placenta	UBERON:0001987	88.49	gold quality
endometrium	UBERON:0001295	88.06	gold quality
mucosa of sigmoid colon	UBERON:0004993	87.75	gold quality
saphenous vein	UBERON:0007318	87.37	gold quality
oral cavity	UBERON:0000167	87.11	gold quality
lower lobe of lung	UBERON:0008949	87.11	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

164 targeting ARL5B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-4525	99.94	64.38	675

Literature-anchored findings (GeneRIF, showing 9)

• ARL8 contains six exons and five introns, and encodes a 179 amino acid protein that shares homology to the other ARL proteins. (PMID:12853149)
• Arl8 and SKIP are required for lysosomes to distribute away from the microtubule-organizing center. We identify two kinesin light chain binding motifs in SKIP that are required for lysosomes to accumulate kinesin-1 and redistribute to the cell periphery. (PMID:22172677)
• Arl5b is a trans-golgi-network-localised small G protein that plays a key role in regulating transport along the endosome-trans-golgi network pathway (PMID:22245584)
• Depletion of either Arl5b or AP4 results in the accumulation of APP. (PMID:28000370)
• Advanced glycation end products reduce macrophage-mediated killing of Staphylococcus aureus by ARL8 upregulation and inhibition of autolysosome formation. (PMID:32250445)
• miR-145 inhibits mitochondrial function of ovarian cancer by targeting ARL5B. (PMID:33419459)
• Binding with heat shock cognate protein HSC70 fine-tunes the Golgi association of the small GTPase ARL5B. (PMID:34798070)
• Knockdown of ARL5B Induces Mitochondrial-mediated Apoptosis and Inhibits Glycolysis in Breast Cancer Cells by Activating MDA5 Signaling. (PMID:35546774)
• Interacting partners of Golgi-localized small G protein Arl5b identified by a combination of in vivo proximity labelling and GFP-Trap pull down. (PMID:35789482)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	arl8	ENSDARG00000094709
mus_musculus	Arl5b	ENSMUSG00000017418
rattus_norvegicus	Arl5b	ENSRNOG00000064112
drosophila_melanogaster	Arl5	FBGN0035866

Paralogs (30): ARF5 (ENSG00000004059), SAR1A (ENSG00000079332), ARFRP1 (ENSG00000101246), TRIM23 (ENSG00000113595), ARL6 (ENSG00000113966), ARL1 (ENSG00000120805), ARL4A (ENSG00000122644), ARL8B (ENSG00000134108), ARF3 (ENSG00000134287), ARL3 (ENSG00000138175), ARL5C (ENSG00000141748), ARF1 (ENSG00000143761), ARL8A (ENSG00000143862), ARL11 (ENSG00000152213), SAR1B (ENSG00000152700), ARL5A (ENSG00000162980), ARF6 (ENSG00000165527), ARF4 (ENSG00000168374), ARL13B (ENSG00000169379), ARL13A (ENSG00000174225), ARL10 (ENSG00000175414), ARL4D (ENSG00000175906), ARL14 (ENSG00000179674), ARL15 (ENSG00000185305), ARL17A (ENSG00000185829), ARL4C (ENSG00000188042), ARL9 (ENSG00000196503), ARL2 (ENSG00000213465), ARL16 (ENSG00000214087), ARL17B (ENSG00000228696)

Protein

Protein identifiers

ADP-ribosylation factor-like protein 5B — Q96KC2 (reviewed: Q96KC2)

Alternative names: ADP-ribosylation factor-like protein 8

All UniProt accessions (2): B0YIW9, Q96KC2

UniProt curated annotations — full annotation on UniProt →

Function. Binds and exchanges GTP and GDP.

Similarity. Belongs to the small GTPase superfamily. Arf family.

RefSeq proteins (1): NP_848930* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005225	Small_GTP-bd	Domain
IPR006689	Small_GTPase_ARF/SAR	Family
IPR024156	Small_GTPase_ARF	Family
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00025

UniProt features (25 total): helix 10, strand 6, binding site 5, initiator methionine 1, chain 1, turn 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1YZG	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96KC2-F1	92.55	0.82

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 23–30; 31; 66–70; 125–128; 159

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 218 (showing top): GSE45365_NK_CELL_VS_BCELL_DN, GSE45365_NK_CELL_VS_BCELL_UP, HORIUCHI_WTAP_TARGETS_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GCANCTGNY_MYOD_Q6, GOBP_VESICLE_MEDIATED_TRANSPORT, GTGCCTT_MIR506, GOCC_TRANS_GOLGI_NETWORK, MYOD_01, GATA1_01, ZIC1_01, GARY_CD5_TARGETS_DN, HTF_01, DOUGLAS_BMI1_TARGETS_DN

GO Biological Process (3): intracellular protein transport (GO:0006886), vesicle-mediated transport (GO:0016192), protein localization to Golgi membrane (GO:1903292)

GO Molecular Function (4): GTPase activity (GO:0003924), GTP binding (GO:0005525), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), trans-Golgi network (GO:0005802)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	1
protein transport	1
intracellular transport	1
transport	1
cellular process	1
protein localization to Golgi apparatus	1
protein localization to membrane	1
ribonucleoside triphosphate phosphatase activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
Golgi apparatus subcompartment	1

Protein interactions and networks

STRING

2457 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARL5B	PLEKHM2	Q8IWE5	953
ARL5B	KIF1A	Q12756	759
ARL5B	KLC2	Q9H0B6	699
ARL5B	TOM1	O60784	694
ARL5B	KLC1	Q07866	690
ARL5B	PLEKHM1	Q9Y4G2	683
ARL5B	KLC3	Q6P597	665
ARL5B	KLC4	Q9NSK0	645
ARL5B	BORCS8	Q96FH0	622
ARL5B	KXD1	Q9BQD3	606
ARL5B	BORCS5	Q969J3	597
ARL5B	BORCS7	Q96B45	596
ARL5B	BORCS6	Q96GS4	583
ARL5B	FYCO1	Q9BQS8	558
ARL5B	RUFY4	Q6ZNE9	552

IntAct

37 interactions, top by confidence:

A	B	Type	Score
ARL5B	FNDC11	psi-mi:“MI:0915”(physical association)	0.560
SLC5A5	SLC19A2	psi-mi:“MI:0914”(association)	0.530
RRM1	GLRX3	psi-mi:“MI:0914”(association)	0.530
TIMMDC1	NDUFC2	psi-mi:“MI:0914”(association)	0.530
SRPRB	CTDNEP1	psi-mi:“MI:0914”(association)	0.530
VPS36	UBB	psi-mi:“MI:0914”(association)	0.530
PDCD1	TMEM223	psi-mi:“MI:0914”(association)	0.350
AKAP14	EFCAB7	psi-mi:“MI:0914”(association)	0.350
GRPR	GPR89A	psi-mi:“MI:0914”(association)	0.350
SLC20A1	MPP2	psi-mi:“MI:0914”(association)	0.350
SRPRB	GOSR1	psi-mi:“MI:0914”(association)	0.350
SYP	APBB1	psi-mi:“MI:0914”(association)	0.350
LPAR6	DEGS1	psi-mi:“MI:0914”(association)	0.350
PTGIR	GPAA1	psi-mi:“MI:0914”(association)	0.350
EDNRA	BCL2L11	psi-mi:“MI:0914”(association)	0.350
GNAT1	DNAJC6	psi-mi:“MI:0914”(association)	0.350
IL4R	DHRS3	psi-mi:“MI:0914”(association)	0.350
SGK1	HRAS	psi-mi:“MI:0914”(association)	0.350
CD164L2	SLC19A1	psi-mi:“MI:0914”(association)	0.350
CENPO	ITGB3BP	psi-mi:“MI:0914”(association)	0.350
ARL5B	RAD21	psi-mi:“MI:0914”(association)	0.350
FFAR1	SLC12A8	psi-mi:“MI:0914”(association)	0.350
KLRB1	ESYT2	psi-mi:“MI:0914”(association)	0.350
UPK2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
HLA-DMB	RAB29	psi-mi:“MI:0914”(association)	0.350
TNFRSF9	WFS1	psi-mi:“MI:0914”(association)	0.350
ARL5B	ATP1A3	psi-mi:“MI:0914”(association)	0.350

BioGRID (91): ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS), ARL5B (Affinity Capture-MS)

ESM2 similar proteins: A4D1S5, A6NH57, O45379, O59781, O88848, P25160, P25378, P34212, P38116, P40994, P51152, P51646, Q02804, Q0IIM2, Q13795, Q18510, Q2KJ96, Q32LJ2, Q3SXC5, Q54E92, Q54HK2, Q54I24, Q54JJ3, Q54V41, Q54V47, Q54Y14, Q54YV7, Q55AD9, Q5JT25, Q5M9P8, Q5R4G5, Q5R579, Q5RCQ6, Q60Z38, Q61DE0, Q63055, Q6P068, Q6P3A9, Q80ZU0, Q8BXL7

Diamond homologs: A6NH57, B5FYQ0, O00909, O23778, O48649, O48920, P0CM16, P0CM17, P0DH91, P11076, P18085, P19146, P22274, P25160, P26990, P26991, P34212, P34727, P36397, P36405, P36406, P36407, P36579, P37996, P38116, P40616, P40940, P40945, P40946, P40994, P49076, P49702, P51643, P51644, P51645, P51646, P51821, P51822, P51823, P51824

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	13
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

901 predictions. Top by Δscore:

Variant	Effect	Δscore
10:18659682:AGGT:A	donor_loss	1.0000
10:18659683:GGTG:G	donor_loss	1.0000
10:18666573:A:AG	acceptor_gain	1.0000
10:18666574:G:GG	acceptor_gain	1.0000
10:18666633:ATT:A	donor_gain	1.0000
10:18666636:G:GG	donor_gain	1.0000
10:18668528:A:AG	acceptor_gain	1.0000
10:18668529:G:GG	acceptor_gain	1.0000
10:18668529:GCTT:G	acceptor_gain	1.0000
10:18668529:GCTTA:G	acceptor_gain	1.0000
10:18672609:A:AG	acceptor_gain	1.0000
10:18672620:A:AG	acceptor_gain	1.0000
10:18672621:G:GA	acceptor_gain	1.0000
10:18672621:GTTC:G	acceptor_gain	1.0000
10:18672701:ATGAG:A	donor_loss	1.0000
10:18672702:TGAGG:T	donor_loss	1.0000
10:18672704:AGG:A	donor_loss	1.0000
10:18672705:GG:G	donor_loss	1.0000
10:18672706:GTAA:G	donor_loss	1.0000
10:18672707:T:G	donor_loss	1.0000
10:18673980:GCA:G	acceptor_loss	1.0000
10:18673981:CAGGA:C	acceptor_loss	1.0000
10:18673982:A:AC	acceptor_loss	1.0000
10:18673982:A:AG	acceptor_gain	1.0000
10:18673982:AG:A	acceptor_gain	1.0000
10:18673983:G:GA	acceptor_gain	1.0000
10:18673983:GG:G	acceptor_gain	1.0000
10:18673983:GGAT:G	acceptor_gain	1.0000
10:18673983:GGATT:G	acceptor_gain	1.0000
10:18674131:GAAGG:G	donor_gain	1.0000

AlphaMissense

1178 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:18666610:G:T	G28W	1.000
10:18666614:A:T	K29I	1.000
10:18668619:A:C	D66A	1.000
10:18674021:A:T	K126I	1.000
10:18674022:A:C	K126N	1.000
10:18674022:A:T	K126N	1.000
10:18666595:G:A	G23R	0.999
10:18666595:G:C	G23R	0.999
10:18666596:G:A	G23E	0.999
10:18666610:G:A	G28R	0.999
10:18666610:G:C	G28R	0.999
10:18666611:G:A	G28E	0.999
10:18666611:G:T	G28V	0.999
10:18666613:A:C	K29Q	0.999
10:18666615:A:C	K29N	0.999
10:18666615:A:T	K29N	0.999
10:18666617:C:T	T30I	0.999
10:18668568:G:A	G49E	0.999
10:18668615:T:A	W65R	0.999
10:18668615:T:C	W65R	0.999
10:18668618:G:C	D66H	0.999
10:18668619:A:G	D66G	0.999
10:18668619:A:T	D66V	0.999
10:18668651:T:A	W77R	0.999
10:18668651:T:C	W77R	0.999
10:18668653:G:C	W77C	0.999
10:18668653:G:T	W77C	0.999
10:18674020:A:G	K126E	0.999
10:18674021:A:C	K126T	0.999
10:18666613:A:G	K29E	0.998

dbSNP variants (sampled 300 via entrez): RS1000019736 (10:18673760 ATT>A,AT,ATTT), RS1000235601 (10:18666977 C>T), RS1000284909 (10:18669387 A>G,T), RS1000421865 (10:18681368 A>G,T), RS1000436293 (10:18664165 G>C), RS1000497169 (10:18676676 A>G), RS1000498975 (10:18673607 A>G), RS1000562141 (10:18659384 A>G), RS1000615368 (10:18671641 C>G), RS1000769139 (10:18666790 A>G), RS1000819106 (10:18677901 T>G), RS1001071703 (10:18671877 C>G,T), RS1001309523 (10:18658498 C>G), RS1001349551 (10:18678640 T>C), RS1001380935 (10:18658690 C>G)

Disease associations

OMIM: gene MIM:608909 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002975_3	Postoperative atrial fibrillation in coronary artery bypass grafting surgery	7.000000e-06
GCST003209_4	Colorectal or endometrial cancer	2.000000e-07
GCST004521_192	Autism spectrum disorder or schizophrenia	3.000000e-10
GCST006281_11	Coronary artery disease in type 1 diabetes	6.000000e-06
GCST008118_20	Suicide attempts in major depressive disorder	3.000000e-08
GCST011999_3	Hepatitis C (spontaneous viral clearance)	2.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004230	endometrial neoplasm
EFO:0004321	attempted suicide
EFO:0009785	remission

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

65 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects cotreatment, decreases expression, increases abundance, increases expression	3
Nickel	increases expression	3
Cyclosporine	increases expression	3
sodium arsenite	decreases expression, increases expression	2
entinostat	increases expression, affects cotreatment	2
Smoke	increases abundance, decreases expression	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	decreases expression	2
Cadmium Chloride	increases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	increases expression	1
methylmercuric chloride	decreases expression, increases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
pirinixic acid	affects binding, increases activity, increases expression	1
trichostatin A	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
manganese chloride	increases abundance, increases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects response to substance	1
15-acetyldeoxynivalenol	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
pentabromodiphenyl ether	increases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
torcetrapib	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery